Cumulative incidence of TT-CMV among 807 transplant recipients, according to transfusion strategy.

During period 1, 360 patients were supported with only CMV-seronegative or filtered blood products from CMV-positive donors, whereas during period 2, 447 patients were also supported with platelets obtained via apheresis from CMV-positive donors without further filtration.